Among primary central nervous system tumors in adults, gliomas are the most prevalent and are linked to significant morbidity and mortality. Despite standard treatment options, including surgery, radiation therapy, and temozolomide chemotherapy, patient outcomes remain dismal, with median overall survival ranging from 4.9 to 20.5 months. This underscores the urgent need for innovative glioma therapies.

Immunogenic tumor-cell death (ICD) is a promising approach that not only destroys cancer cells but also activates a specific anti-tumor immune response. Ferroptotic cell death, a form of regulated cell death, can exhibit features of ICD. The primary objective of this project is to develop dendritic cell vaccines loaded with ferroptotic tumor lysates to achieve more effective glioma immunotherapy.